KalVista Pharmaceuticals (KALV) Long-Term Debt Issuances (2014 - 2015)
KalVista Pharmaceuticals recorded quarterly Long-Term Debt Issuances of $4.0 million in Q1 2015, down 29.92% quarter-over-quarter from $5.7 million in Q4 2014.
KalVista Pharmaceuticals' Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at $4.0 million for Q1 2015.
- In Q1 2015, Long-Term Debt Issuances changed N/A year-over-year to $4.0 million; the TTM figure through Dec 2015 stood at $4.0 million (changed N/A YoY), while the FY2015 annual figure was $4.0 million, down 20.0% from the prior year.
- Long-Term Debt Issuances came in at $4.0 million for Q1 2015 at KalVista Pharmaceuticals, down from $5.7 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $5.7 million in Q4 2014 to a low of $4.0 million in Q1 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2015 | 4.00 Mn |
| Mar 31, 2015 | 4.00 Mn |
| Dec 31, 2014 | 5.71 Mn |
| Dec 31, 2014 | 5.71 Mn |